Price Chart

Profile

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
URL https://www.allakos.com
Investor Relations URL https://investor.allakos.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 06, 2024 (est.)
Last Earnings Release Nov. 13, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
URL https://www.allakos.com
Investor Relations URL https://investor.allakos.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Mar. 06, 2024 (est.)
Last Earnings Release Nov. 13, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A